Special Issue

Small Molecule Drug Discovery: Driven by In-Silico Techniques

Message from the Guest Editor

Small molecules are one type of drugs that are commonly used in medicine. They are typically synthesized chemically and are generally less complex than biologics. Generally, small molecules are designed to interact with specific targets involved in disease processes, such as enzymes or receptors. Moreover, the field of small-molecule drug design is a constantly developing area that benefits from advances in computational tools and methodologies. With the help of these tools, scientists can better design and optimize small-molecule drug candidates. In particular, ligandbased methods are critical tools for virtual screening, with pharmacophore modeling, 3D-QSARs, CoMSIA, and CoMFA being the most significant. Structure-based drug design is a highly specific, efficient, and rapid process that focuses on the 3D structure of a target protein and the disease knowledge at the molecular level. This Special Issue aims to present the latest advances in the discovery, design, synthesis, and pharmacological evaluation of small molecules driven by computational approaches.

Guest Editor

Dr. Roberta Rocca

Dipartimento di Scienze della Salute, Università "Magna Graecia" di Catanzaro, Campus "Salvatore Venuta", Viale Europa, 88100 Catanzaro, Italy

Deadline for manuscript submissions

25 February 2025



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.3 CiteScore 6.1 Indexed in PubMed



mdpi.com/si/196970

Pharmaceuticals MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.3 CiteScore 6.1 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Pharmaceutical Science)